Coverage / GILD / Trade Card

GILD

Gilead Sciences, Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 167.95 Healthcare - Drug Manufacturers - GeneralREDUCE ZONE
ACTIONABLEMethodology gates passed
62

Position levels

Currenttoday
USD 167.95
Buy <=wait / entry
USD 130.33
Trim >=take some off
USD 155.00
Thesis breakA material clinical trial failure in a named late-stage pipeline candidate, a do...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case30%100 / 10030.0
Base case49%62 / 10030.4
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • M&A activity: Gilead Sciences and Lakefront Biotherapeutics completed acquisition of Ouro Medicines to expand inflammation pipeline
  • Earnings or guidance changes: Raised 2026 sales outlook and increased quarterly dividend by 3.8%
  • Earnings or guidance changes: Q2 revenue of 7.8B driven primarily by HIV franchise
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n